HM Payson & Co’s Ionis Pharmaceuticals IONS Stock Holding History

HM Payson & Co’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-360	Closed	-$14.8K	–	1027
2023 Q2	$14.8K	Buy	+360	New	+$13.8K	﹤0.01%	761

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

HM Payson & Co's IONS Position: Q3 2023 in Review

HM Payson & Co sold out of Ionis Pharmaceuticals (IONS) in Q3 2023, closing a stake of 360 shares — an estimated $14.8K sold.

HM Payson & Co first reported a position in IONS in Q2 2023 and held it in 1 quarter. The position peaked at $14.8K in Q2 2023. 310 funds tracked by Wall St. Rank hold IONS as of Q3 2023.

HM Payson & Co reported no remaining Ionis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
HM Payson & Co sold 360 Ionis Pharmaceuticals shares in Q3 2023, an estimated $14.8K.
HM Payson & Co first reported a position in Ionis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
HM Payson & Co's Ionis Pharmaceuticals position peaked at $14.8K in Q2 2023.
310 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2023.

Based on HM Payson & Co's 13F filing for Q3 2023, filed 6 Nov 2023.